Kineta, Inc. (KANT)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Next-generation Immunotherapies	5.44M	Log In	Log In	Log In
Next-generation Immunotherapies Growth	178.65%	Log In	Log In	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
United States	5.44M	Log In	Log In	Log In
United States Growth	178.65%	Log In	Log In	Log In